Bladder Cancer VL

The Microbiome's Impact on the Immunotherapy of Genitourinary Cancers - Sumanta Kumar Pal

Details
Ashish Kamat and Professor Sumanta (Monty) Pal discuss the microbiome's influence on genitourinary cancers and immunotherapy. Highlighting foundational research, Dr. Pal explains how the gut microbiome composition affects immunotherapy outcomes, with variability in bacterial species linked to treatment responses. He emphasizes the detrimental impact of antibiotics on immunotherapy efficacy and int...

Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC - Stephen Boorjian

Details
Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary endpoint...

Bladder Cancer: En Bloc Resection Technique Shows Promise - David D'Andrea

Details
Ashish Kamat welcomes David D'Andrea to discuss the eBLOC trial, focusing on en-bloc versus conventional resection of bladder tumors. He highlights the historical context of TURB (Transurethral Resection of Bladder Tumor) and its limited evolution over the years. The eBLOC trial, designed to compare en-bloc and conventional TURB, aimed to improve the quality of resection, crucial for accurate stag...

Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? - Amanda Myers

Details
Amanda Myers presents a comprehensive review on lymph node dissection in GU cancers as of 2023. She emphasizes its critical role in surgical urologic care for accurate staging and detecting micrometastases. The review, based on systematic research from 2014 to 2023, covers bladder, upper tract, kidney, prostate, and penile cancers. Key findings include the recommendation of standard pelvic lymph n...

Chinese Trial Shows Blue Light Cystoscopy Superior for Bladder Cancer Detection - Hongxian Zhang

Details
Ashish Kamat welcomes Hongxian Zhang to present a phase III study comparing blue light cystoscopy (BLC) with white light cystoscopy (WLC) for bladder cancer detection in China. Conducted across seven hospitals from November 2022 to June 2023, the study involved 158 patients, with 114 remaining in the final analysis. It demonstrates that BLC, especially with Hexaminolevulinate (HAL) and modern 4K L...

BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson

Details
Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. The phase 3 study showed a 75.7% complete response at any time point, with 7...

Exploring Promising Therapies and Genomic Insights in Bladder Cancer Research - Laura Bukavina

Details
Ashish Kamat welcomes Laura Bukavina to discuss highlights from the SUO 2023 meeting, focusing on bladder cancer research. Dr. Bukavina emphasizes the BOND-003 study on cretostimogene (creto), an adenovirus targeting bladder cancer cells with defective retinoblastoma genes. Creto shows a 75.7% complete response rate, with 74.4% lasting over six months. Another key topic is the ENVISION trial, exam...

Bladder Cancer Patients Experience High Burden From Current Intravesical Therapy Model - Amanda Myers

Details
Ruchika Talwar interviews Amanda Myers about her study on at-home intravesical therapy for bladder cancer patients. Dr. Myers' was inspired by patients' desire for a more convenient treatment method. The study, conducted through a cross-sectional survey of the BCAN Patient Survey Network, involved 233 respondents who had undergone at least one dose of intravesical therapy. Key findings include sig...

Phase 2 Trial: Chemotherapy Plus Immunotherapy Facilitates Bladder Sparing in Muscle-Invasive Bladder Cancer - Matthew Galsky

Details
Ashish Kamat and Matthew Galsky discuss a phase 2 trial on organ sparing for muscle-invasive bladder cancer, published in Nature Medicine. Dr. Galsky highlights the trial's focus on systemic therapy as an alternative to cystectomy, noting its potential for curative outcomes. The study involved patients receiving gemcitabine-cisplatin plus nivolumab, followed by clinical restaging to identify clini...

Leaders Establish Consensus Criteria for High-Risk Bladder Cancer Trials, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the Society for Immunotherapy of Cancer and the International Bladder Cancer Group's recommendations for clinical trial design in high-risk non-muscle-invasive bladder cancer. The consensus statement, led by Dr. Ashish Kamat and published in the Journal of Clinical Oncology, aims to guide investigators in late-phase clinical trial design. The panel, comprisi...